German SME specializing in genetic information management systems for clinical pharmacogenomics and precision medicine applications.
BIO.LOGIS Genetic Information Management (bGIM GmbH) is a Frankfurt-based SME specializing in the management and clinical application of genetic information, with a clear focus on pharmacogenomics — the use of a patient's genetic profile to guide drug prescribing decisions. Their work sits at the intersection of genomic data systems and clinical practice, translating raw genetic data into actionable information that clinicians can use at the point of care. In H2020, they contributed to projects defining the future architecture of genetics clinics and deploying pharmacogenomic data across European health systems at scale. They function as a specialized informatics and data management provider within large clinical research consortia.
Both GCOF and U-PGx are directly focused on making pharmacogenomic data accessible and actionable in clinical settings, which aligns precisely with the company's stated business of genetic information management.
GCOF explicitly addresses the architecture of a 'Genetics Clinic of the Future', indicating expertise in how genetic information systems are designed and operated within healthcare environments.
U-PGx (2016–2021) focused on making pharmacogenomic data ubiquitous across European healthcare, placing bGIM in the implementation layer of precision medicine rollout.
With only two projects, both launched within a year of each other (2015–2016), there is no meaningful temporal evolution to trace — bGIM entered H2020 with a focused, consistent profile and did not shift direction. The progression between projects does reveal a scale-up logic: GCOF was a small coordination action (EUR 72,500) that conceptualized future genetics clinic models, while U-PGx was a full research action (EUR 2.2M) implementing pharmacogenomics across real clinical systems in multiple countries. This suggests a deliberate path from concept to deployment, not a change in focus but a deepening of the same specialization.
bGIM appears to be moving from conceptual groundwork toward operational implementation of pharmacogenomics in clinical systems — a potential partner for anyone building infrastructure around genomic data in healthcare.
bGIM has never led an H2020 project — both participations are as a consortium partner, suggesting they contribute specialized capability rather than project management or scientific coordination. Despite their small size as an SME, they operate in large, international consortia (31 partners across 14 countries), which indicates they are comfortable integrating into complex multi-partner projects. This profile — specialist contributor in large consortia — means working with them likely means engaging a focused, technically specific team rather than a broad delivery partner.
bGIM has built connections with 31 unique partners across 14 countries through just two projects, almost entirely through the large U-PGx consortium, which had broad European participation across academic medical centers and health systems. Their network is wide by project count but shallow in terms of repeated partnerships.
bGIM occupies a rare niche as a private SME focused specifically on genetic information management for clinical use — most actors in this space are either large hospital systems, academic genomics centers, or generalist health IT vendors. Their combination of a company identity built entirely around genetic data management and demonstrated participation in Europe's leading pharmacogenomics research project (U-PGx) gives them credibility that generic IT companies cannot easily replicate. For consortium builders in precision medicine or pharmacogenomics, they represent a ready-made specialist partner who can handle the data layer without needing to be trained on the domain.
